Pfizer’s Plans To Market Accupril As A “Branded Generic” Challenged By Teva
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer intends to sell generic quinapril through its Greenstone subsidiary as soon as Teva triggers its own 180-day marketing exclusivity for the ACE inhibitor, Teva’s citizen petition to FDA states. Teva asserts Pfizer should be required to file a preapproval supplemental NDA before marketing the generic.